Eleven Biotherapeutics Appoints Paul Chaney To Its Board Of Directors
Published: Mar 03, 2014
Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company’s board of directors.
Help employers find you! Check out all the jobs and post your resume.